一般社団法人JBCRG学会発表
2023年
Health-Related QOL and Physical Activity Collected via Wearable Device in Patients With HR+/HER2–Advanced Breast Cancer in Japan. Treated With Palbociclib+Endocrine Therapy (ET) or ET Alone: 6-Month Longitudinal Study (JBCRG-26)
Hiroko Bando, Mari Oba, Aya Ueda, Kaori Terata, Mihoko Doi, Shigenori Nagai, Masaya Hattori, Kenichi Watanabe, Nobuko Tamura, Manabu Futamura, Kei Koizumi, Naoki Niikura, Tempei Miyaji, Yasuaki Muramatsu, Linghua Xu, Norikazu Masuda, Shigehira Saji
San Antonio Breast Cancer Symposium, 2023 Dec, Texas USA (Poster)
Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Hatem A Azim J, Samuel M Niman, Ann H Partridge, Isabelle Demeestere, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B. Saetersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Janice M. Walshe, Manuel Ruíz-Borrego, Halle C F Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, N. J. Klar, Tanja. Spanic, Kathryn Ruddy, Martine Piccart, Larissa A Korde, Aron Goldhirsch †, Richard D Gelber, Olivia Pagani, Fedro A Peccatori
San Antonio Breast Cancer Symposium, 2023 Dec, Texas USA (Oral)
HR陽性HER2陰性進行転移乳癌のアベマシクリブによる一次治療中のESR1変異に基づく治療戦略の検討：JBCRG M08（AMBER試験）
大城智弥、吉波哲大、笹田伸介、岩瀬まどか、坂東裕子、石原幹也、寺田かおり、吉本信保、田辺真彦、髙田正泰、秋吉清百合、森田智視、増田慎三
第21回日本乳癌学会近畿地方会, 2023 Nov, Osaka, Japan（一般演題）
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, Toshitaka Okuno, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
ESMO, 2023 Oct, Madrid Spain (ポスター)
原発性HER2陽性乳癌に対するT-DM1術前薬物療法の可能性(JBCRG-20)
増田慎三, 伊藤充矢, 田辺裕子, 井上賢一, 河口浩介, 八十島宏行, 高野利実, 坂東裕子, 中村力也, 山中隆司, 石田和茂, 有賀智之, 柳田康弘, 徳永えり子, 青儀健二郎, 大野真司, 笠井宏委, 片岡竜貴, 森田智視, 戸井雅和
第31回日本乳癌学会学術総会, 2023 Jul, Yokohama (ポスター)
ER陽性/HER陰性進行再発乳癌に対する酢酸メドロキシプロゲステロンの有効性に関する検討
冨口麻衣, 川口英俊, 山本豊, 佐治重衡, 増田慎三, 中山貴寛, 青儀健二郎, 阿南敬生, 大谷彰一郎, 金子耕司, 徳永えり子, 中村清吾, 長谷川善枝, 服部正也, 藤澤知巳, 森田智視, 山口美樹, 山下年成, 戸井雅和, 大野真司
第31回日本乳癌学会学術総会, 2023 Jul, Yokohama (ポスター)
進行・再発乳癌におけるリアルワールドエビデンスの課題と展望
相良安昭
第31回日本乳癌学会学術総会, 2023 Jun, Yokohama (シンポジウム）
乳癌における包括的ゲノム診療の実際-JBCRG REIWA studyを通して-
増田紘子, 多田寛, 服部正也, 古川孝広, 原文堅, 田辺裕子, 相良安昭, 北川大, 枝園忠彦, 岩谷胤生, 八十島宏行, 上本康明, 吉村健一, 岩田広治, 増田慎三
第31回日本乳癌学会学術総会, 2023 Jun, Yokohama (シンポジウム)
Pertuzumab retreatment in patients with HER2-positive locally advanced/ metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Naruto Taira, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda
ASCO, 2023 Jun, Chigago USA (Poster Discussion Session)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
Kenichi Inoue, Norikazu Masuda, Toshimi Takano, Mitsuya Ito, Yuko Tanabe, Kosuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R. Kataoka, Satoshi Morita, Masakazu Toi
ESMO Breast Cancer, 2023 May, Berlin Germany (Mini Oral)